Indications of Bempedoic Acid

Indications of Bempedoic Acid

New Drug Positioning and Target Population

Bempedoic acid is a novel drug for the treatment of high cholesterol, mainly indicated for patients who are not suitable for statin therapy and have an inadequate lipid-lowering effect with ezetimibe monotherapy, providing a new therapeutic option for them.

Limitations of Traditional Therapy

For patients at high cardiovascular risk or with hypercholesterolemia, statins are the first-line treatment. However, some patients cannot tolerate statins due to side effects or can only take low doses, creating an urgent need for alternative approaches to control cholesterol.

Role and Shortcomings of Ezetimibe

The National Institute for Health and Care Excellence (NICE) recommends ezetimibe when statins are not tolerated. It is low-cost and well-tolerated, but monotherapy or combination with statins often fails to reduce cholesterol to the recommended target (a reduction of more than 40%).

Filling the Therapeutic Gap

When ezetimibe is insufficient and patients do not meet the strict eligibility criteria for PCSK9 inhibitors, NICE now recommends the combination of bempedoic acid and ezetimibe, specifically for patients unable to take statins and with an inadequate response to ezetimibe monotherapy.

Mechanism of Action of Bempedoic Acid

Targeting Hepatic Cholesterol Synthesis

Similar to statins, bempedoic acid lowers blood cholesterol by reducing cholesterol synthesis in the liver, but acts on a different target, inhibiting ATP-citrate lyase.

Increasing LDL Receptor Number

By inhibiting this enzyme, the liver increases the number of low-density lipoprotein (LDL) receptors, thereby more efficiently clearing LDL cholesterol from the blood and exerting a lipid-lowering effect.

Avoiding Muscular Side Effects

Unlike statins, bempedoic acid acts exclusively in the liver. This liver specificity significantly reduces the likelihood of muscle-related side effects, addressing the key issue of statin intolerance in some patients.

Convenient Dosage Regimen

Two dosage forms are currently available, including single-agent tablets and fixed-dose combination tablets with ezetimibe, both of which can be taken with or without food once daily, greatly improving patient medication adherence.

Lipid-Lowering Efficacy and Onset Time of Bempedoic Acid

Significant Monotherapy Lipid-Lowering Effect

Clinical trials have shown that bempedoic acid monotherapy for 12 weeks reduces low-density lipoprotein cholesterol (LDL-C) levels by 17% to 28%, demonstrating favorable independent lipid-lowering activity.

Synergistic Effect of Combination Therapy

When bempedoic acid is used in combination with ezetimibe, the two agents act synergistically, reducing LDL-C levels by up to 38%, providing robust efficacy for patients with difficult-to-control lipid levels.

Importance of Lifestyle Intervention

While taking cholesterol-lowering medication, maintaining a healthy diet is essential. The combination of pharmacotherapy and lifestyle intervention minimizes cardiovascular disease risk.

Therapeutic Efficacy Assessment Interval

After initiating bempedoic acid, physicians typically schedule cholesterol level rechecks within two to three months to scientifically evaluate the actual therapeutic effect and adjust the subsequent regimen.